Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.49 |
| ▸ | CTSK | P43235 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.41 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.39 |
| ▸ | REN | P00797 | 2/20 | 0.38 |
| ▸ | CTSD | P07339 | 1/20 | 0.38 |
| ▸ | CTSE | P14091 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29526164 | 1.00 | CTSS (0.49) | CTSSCTSKKDM4EHTTCA2 | |
| SCHEMBL24420344 | 0.85 | CTSS (0.53) | CTSSCTSKKDM4EHTTCA2 | |
| SCHEMBL29526580 | 0.85 | CTSS (0.53) | CTSSCTSKKDM4EHTTCA2 | |
| SCHEMBL29526276 | 0.80 | CTSS (0.50) | CTSSCTSKKDM4EHTTCA2 | |
| SCHEMBL24420098 | 0.80 | CTSS (0.50) | CTSSCTSKKDM4EHTTCA2 | |
| SCHEMBL1020140 | 0.80 | CYP17A1 (0.47) | — | |
| SCHEMBL29957148 | 0.80 | CYP17A1 (0.47) | — | |
| SCHEMBL9128016 | 0.75 | TP53 (0.62) | CTSSCTSKKDM4EHTTCA2 | |
| SCHEMBL9128031 | 0.75 | TP53 (0.62) | CTSSCTSKKDM4EHTTCA2 | |
| SCHEMBL9744622 | 0.74 | CTSS (0.55) | CTSSCTSKKDM4EHTTCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098018-A1 | BICYCLIC 1,4-DIAZEPANONES AND THERAPEUTIC USES THEREOF | CYTOKINETICS INC (US) | 2026-04-09 | — | — | US | disclosed |
| CN-116635378-A | Bicyclic 1, 4-diazacycloheptanones and therapeutic uses thereof | 赛特凯恩蒂克公司 | 2023-08-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260098018-A1 | BICYCLIC 1,4-DIAZEPANONES AND THERAPEUTIC USES THEREOF | MYLK2, TNNT2, RYR1 | CTSS 2616/4885CTSK 1366/4885KDM4E 1026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.